Ofatumumab for refractory opsoclonus‐myoclonus syndrome following treatment of neuroblastoma

  title={Ofatumumab for refractory opsoclonus‐myoclonus syndrome following treatment of neuroblastoma},
  author={Tyler G Ketterl and Yoav H. Messinger and Dawn Niess and Elizabeth Gilles and W Keith Engel and Joanna L. Perkins},
  journal={Pediatric Blood \& Cancer},
Opsoclonus‐myoclonus syndrome (OMS) may be associated with ANNA‐1 (anti‐Hu) autoantibodies. The standard treatment with IVIG, steroids, and anti‐CD20 monoclonal antibody may fail, and optimal therapy is unknown. A patient developed OMS with high‐titer ANNA‐1 following recovery from neuroblastoma. She failed standard therapy and had only transient response to rituximab. Treatment with the humanized anti‐CD20 monoclonal antibody ofatumumab combined with methotrexate resulted in transient… 
Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment
Although the neurological symptoms show a good response, most children continue to show neuropsychological disturbances, and children appear to respond regularly to immunosuppressive treatment.
Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome
Review article Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome
New insights are provided on underappreciated risks and pitfalls inherent in relapse, pro-active efforts to avoid progression, the need for early and sufficient treatment beyond corticosteroids and immunoglobulins, and utilization of disease activity biomarkers to identify high-risk patients and safely withdraw immunotherapy.
The Treatment of Opsoclonus-Myoclonus Syndrome Secondary to Neuroblastic Tumours—Single-Centre Experience and Literature Review
NT resection does not resolve OMS in children with OMS secondary to NT, and the combined treatment with dexamethasone plus cyclophosphamide seems to be an effective treatment of OMS.
Current and future approaches for treatment of paraneoplastic neurological syndromes with well-characterized onconeural antibodies
This review is focused on putative T-cell-mediated immunopathogenetic mechanisms and treatment of PNS associated with well-characterized onconeural Abs, which includes anti-Hu, Yo, CV2, Ri, Ma2, amphiphysin and anti-delta/notch-like epidermal growth factor-related receptor.
Tratamiento de la encefalopatía mioclónica de la infancia (síndrome de Kinsbourne) con metotrexate y gammaglobulina endovenosa
Myoclonic encephalopathy of infancy is an important model of natural tumor regression and is probable that neuroblastoma (or viral antigens) and the cerebelum are joint targets of an immunologic attack.
Paraneoplastic neurological syndromes with anti-hu antibodies : Pathogenesis and treatment
This thesis will focus on the immunopathogenesis of PNS with well-characterized onconeural Abs, in particular those with anti-Hu Abs (Hu-PNS).
An Update and Review of the Treatment of Myoclonus
There is a growing body of evidence from head-to-head comparative trials in several types of myoclonus that may help guide therapy, and new therapies for refractory myoc Lonus, including sodium oxybate and deep brain stimulation, are also being explored with increasing enthusiasm.
Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
This review summarizes basic aspects of B-cell biology, discusses the role(s) of B cells in neurological autoimmunity, and presents anti-B-cell drugs that are either currently on the market or are expected to be available in the near future for treating neurological autoimmune disorders.


Ofatumumab for a rituximab‐allergic child with chronic‐relapsing paraneoplastic opsoclonus–myoclonus
Ofatumumab is a fully human anti‐CD20 monoclonal antibody in phase II–III trials for various autoimmune and lymphoreticular diseases. We used it to treat a rituximab‐allergic child with severe,
Immunologic and Clinical Responses to Rituximab in a Child With Opsoclonus-Myoclonus Syndrome
A toddler with moderately severe OMS is treated with rituximab, a monoclonal anti-B cell antibody to clarify the immune response to B-cell depletion and reveal a promising new therapy for OMS that warrants a phase I clinical trial.
Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma.
Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome
CT/MR imaging has the highest detection rate of neuroblastoma and this should be reflected in investigation protocols to achieve the best possible outcome for children with OMS.
Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus.
Patients with neuroblastoma and POM are more likely to harbor antineuronal antibodies than patients without POM, but the frequent presence of antineURonal antibodies suggests that POM is immune-mediated.
Paraneoplastic gastro‐intestinal anti‐Hu syndrome in neuroblastoma
A child with neuroblastoma who presented with gastro‐intestinal disturbances as a result of the anti‐Hu syndrome is reported on and the causative antibodies can be determined to diagnose or exclude this syndrome.
Which antibody and which cancer in which paraneoplastic syndromes?
A practical overview of the tumour associations, and the neurological associations, of the onconeural antibodies is given.
Elimination of antibodies to recombinant enzyme in Pompe's disease.
The successful induction of immune modulation in a CRIM-negative patient with Pompe's disease who continues to be antibody-free at 24 months of age and continues to gain motor milestones is reported.
Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome.
The results support the role of an early diagnosis of OMA in reducing sequelae and encourage the use of new immunosuppressive therapies.
Paraneoplastic encephalomyelopathies: pathology and mechanisms
The neuropathological findings and pathophysiology of paraneoplastic CNS disorders with reference to antigen-specific serology and neurological and oncological contexts are described.